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Background: The interaction between arbekacin and the hemodialysis membrane is unclear. The aim of this study
was to evaluate the adsorption of arbekacin (ABK) onto hemodialysis membranes and to establish a simpler system
for evaluating the adsorption properties of the drug.
Methods: First, small cut pieces of polysulfone or sulfonated polyacrylonitrile (AN69) hollow fiber membranes were
stirred in a solution of ABK for the qualitative assessment. Then, we designed the experimental system that was
approximately 1/100 of the actual size using a small dialyzer “mini-module” of our original design for the
polysulfone or AN69. We circulated ABK solution in this system for the quantitative assessment. Finally, we
administered ABK in subjects undergoing hemodialysis as a clinical trial to evaluate the adsorption of ABK onto
polysulfone or AN69.
Results: In the qualitative assessment, the rates of ABK adsorption onto polysulfone and AN69 were 6.2 ± 2.9 and
49.8 ± 1.8 %, respectively. In the quantitative assessment, although there was almost no change in the circulating
ABK concentration with the use of polysulfone, there was about 68 % decrease in the circulating ABK concentration
with the use of AN69. In the clinical trial, clearance by the dialyzer using AN69 was high at 10 min after starting
dialysis, despite the sieving coefficient being 0. However, reduction of ABK clearance was observed with time; the
removal rate of ABK at the completion of the dialysis using polysulfone or AN69 was about 67 %, with no difference
between the two membranes. The main limitation of this study was the small sample size in the clinical trial.
Conclusions: These findings suggest that ABK is adsorbed onto AN69. Furthermore, the present adsorption
experiment with a mini-module was considered useful as an evaluation system because it was easy to handle, using
less solvent and drugs compared with a previous report, and it reflected the results of the clinical trial.
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Arbekacin is an effective aminoglycoside antibiotic against
methicillin-resistant Staphylococcus aureus (MRSA) and is
widely used in Japan to treat MRSA infection [1]. As
arbekacin has a narrow therapeutic range, therapeutic
drug monitoring (TDM) is considered necessary to ensure
its effectiveness and safety. Japanese TDM guidelines
recommend that the peak serum concentration of arbeka-
cin be kept within the range of 15 to 20 μg/mL because
arbekacin has a strong therapeutic effect when the ratio of* Correspondence: hirata@kumamoto-u.ac.jp
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inhibitory concentration is 8:1 or higher. Furthermore, as
a high trough concentration increases the risk of kidney
damage, it is recommended that the trough concentration
be kept at 2 μg/mL or lower [2]. It is believed that between
70 and 90 % of arbekacin is excreted through the urine
unmetabolized [3–5], so it is necessary to determine
dosages with kidney function in mind. In addition, as
arbekacin is removed through hemodialysis, this must also
be taken into account when determining dosages [5, 6].
Removal of substances through hemodialysis typically
occurs by diffusion or filtration. Moreover, low molecular
weight proteins such as β2 microglobulin are removed bys distributed under the terms of the Creative Commons Attribution 4.0
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sorption of drugs such as the aminoglycoside antibiotic
amikacin onto certain hemodialysis membranes has also
been reported [8–10], so adsorption onto hemodialysis
membranes is one mechanism of drug removal. In a previ-
ous in vitro experiment that we conducted, we found that
arbekacin is adsorbed onto sulfonated polyacrylonitrile
(AN69), a type of hemodialysis membrane [11]. However,
it is unknown whether arbekacin is removed by adsorption
in clinical practice. Moreover, the in vitro experimental
system that we used in our previous study is complicated
because it is at 1/3 scale and requires a large volume of
solvent and drug. The objective of this study was to assess
the absorption properties of arbekacin onto hemodialysis
membranes and to establish a simple system for assessing
the adsorption properties of drugs.
Methods
Qualitative assessment of adsorption using cut
hemodialysis membranes
The hemodialysis membranes used were polysulfone
(APS-SA; Asahi Kasei Medical Co., Ltd., Tokyo, Japan)
and AN69 (FILTRAL12; Baxter Co., Ltd., Tokyo, Japan).
The housing was removed from the dialyzer of each
hemodialysis membrane, and the hollow fibers were
taken out and washed with ddH2O. Subsequently, the
hollow fibers were cut at 5-mm intervals using a razor
blade that had been washed with ethanol to remove the
paraffin. Arbekacin (Habekacin Injection 100 mg; Meiji
Seika Pharma Co., Ltd., Tokyo, Japan) was diluted with
50 mM phosphoric acid (pH 7.4) to a concentration of
20 μg/mL. Hollow fiber fragments (from a 57.5-cm2
membrane surface area) were added to arbekacin solution
(50 mL) and were agitated for 30 min at 37 °C (Fig. 1a). A
control run was performed using the same procedures
without adding the hollow fiber fragments, and arbekacin
solution was collected before and after the start of theFig. 1 Qualitative assessment of interaction of arbekacin with dialysis mem
Results shown are mean ± standard deviation (n = 3). *P < 0.05, compared wexperiment. The rate of adsorption was calculated using
the following equation.
Mads ¼ Ccon‐Cmemð Þ = Ccon  100
Mads is the rate of adsorption (%), Ccon is the control
concentration (μg/mL), and Cmem is the concentration
after addition of hemodialysis membrane and 30 min of
agitation (μg/mL).
The experimental system was designed to be approxi-
mately 1/200 of actual size (i.e., 10 L of extracellular
fluid and a membrane surface area of 1.15 m2). The
above experiment was run in triplicate.
Quantitative assessment of in vitro adsorption using a
mini-module
The housing was removed from polysulfone and AN69
dialyzers, and the hollow fibers were taken out. Fibers from
a membrane surface area of 115 cm2 were measured out.
There were 70 hollow fibers from the polysulfone mem-
brane and 82 from the AN69 membrane. These hollow
fibers were put through an acrylic pipe connected to the
dialysate port (internal diameter, 7 mm; external diameter,
10 mm; length, 15 cm); after which, both ends were secured
with an epoxy resin adhesive (Quick5; Konishi Co., Ltd.,
Osaka, Japan). Subsequently, both ends were covered with
a blood port cap and were secured with adhesive to create
a mini-module. To ensure that the hollow fibers were not
damaged and there were no leaks from the connections,
the dialysate port was plugged and air was sucked out of
the opposite port using a syringe. Arbekacin was diluted
with 50 mM phosphoric acid (pH 7.4) to a concentration
of 20 μg/mL. The mini-module was connected to a peri-
staltic pump and 50 mM phosphoric acid (pH 7.4) was
circulated through it at 2 mL/min for 30 min to clean it.
Subsequently, arbekacin solution (100 mL) was circulatedbranes. a Experimental device. b Adsorption rate of arbekacin.
ith AN69. AN69 sulfonated polyacrylonitrile
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alysate was not used, the flow rate of the arbekacin solu-
tion was 2 mL/min, and the flow rate of the filtrate was
0.6 mL/min. The filtrate obtained through ultrafiltration
was circulated through again as arbekacin solution
(Fig. 2a). With this method, the decrease in the concentra-
tion of the circulating arbekacin solution is believed to re-
flect the adsorption of arbekacin onto the hemodialysis
membrane [12]. The arbekacin solution and the filtrate
were collected in 200-μL samples. Samples were collected
at the start of circulation and 60, 120, and 240 min (i.e.,
the end of circulation) later when polysulfone was used
and at the start of circulation and 30, 60, 90, 120, 150,
180, and 240 min (i.e., the end of circulation) later when
AN69 was used. When samples were collected, arbekacin
solution at the original concentration was added to re-
plenish the collected amount. The experimental system
was designed to be approximately 1/100 of actual size (i.e.,
10 L of extracellular fluid, a membrane surface area of
1.15 m2, and a blood flow rate of 200 mL/min). The above
experiment was run in triplicate.
Clinical study
1. SubjectsFig
conThe subjects were patients with MRSA infection
who were at least 20 years old and on maintenance
hemodialysis at the Blood Purification Center of
Saiseikai Kumamoto Hospital between November
2010 and September 2014. Patients using an
angiotensin-converting enzyme inhibitor, patients. 2 Quantitative assessment of interaction of arbekacin with dialysis memb
centration over time. Results shown are mean ± standard deviation (n = 3)with a history of hypersensitivity to aminoglycoside
antibiotics, patients with a family history of hearing
impairment related to aminoglycoside antibiotics or
any other kind of hearing impairment, and patients
in whom proper evaluation and adequate follow-up
were deemed by the study doctor to be impossible
were excluded from the study.
2. Research ethics
This clinical study was approved by the Clinical
Research and Medical Technology Ethics
Committee of Kumamoto University (Advanced
Medical Care No. 1111) and the ethics committee of
Saiseikai Kumamoto Hospital, and was conducted in
accordance with the Declaration of Helsinki. It was
conducted in collaboration with doctors at the
Blood Purification Center of Saiseikai Kumamoto
Hospital after obtaining freely given written
informed consent from subjects. To fully ensure
patients’ privacy, data were anonymized so that
patients could not be identified by their names or
other personal information.
3. Drug administration and blood collection
When the first dose of arbekacin was administered,
either 200 or 250 mg was administered via
intravenous infusion over 30 min. After that, a 200- or
250-mg dose was administered via intravenous
infusion over 30 min after hemodialysis. A polysulfone
hemodialysis membrane was used for the first
hemodialysis session after arbekacin administration,
and AN69 was used for the second hemodialysis
session. Samples were collected 30 min after the firstranes. a In vitro experimental device. b Changes in arbekacin
. *P < 0.05, compared with 0 min. AN69 sulfonated polyacrylonitrile
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of hemodialysis with polysulfone (C2), 30 min after
the second dose of arbekacin was administered (C5),
at the start of hemodialysis with AN69 (C6), 1 h after
the start of hemodialysis (C9), 2 h after the start of
hemodialysis (C10), and 30 min after the third dose of
arbekacin was administered (C11). Additionally, at
10 min after the start of hemodialysis, only blood was
circulated without dialysate in order to obtain the
ultrafiltrate. At that time, blood from the dialyzer inlet
(C3, C7) and outlet (C4, C8) was collected along with
the ultrafiltrate (F1, F2) (Fig. 3). Blood and ultrafiltrate
were each collected as 1-mL samples. Plasma was
isolated from collected blood by centrifugation at
3000 rpm for 10 min. The plasma and ultrafiltrate
were stored at −80 °C until the arbekacin
concentration was measured.
4. Assessment of pharmacokinetics and removal by
hemodialysis
The plasma concentration at the end of
hemodialysis, the half-life (t1/2) on and off
hemodialysis, and total body clearance were
calculated from plasma concentrations at C1
through C11. The rate of removal by hemodialysis
was calculated using the following equation.
R ¼ Cstart– Cendð Þ = Cstart
R is the rate of removal by hemodialysis (%), Cstart isFig
bloothe plasma concentration at the start of
hemodialysis (C2 or C6) (μg/mL), and Cend is the. 3 Protocol for the clinical trial. Arbekacin was administered via intravenous in
d was circulated without dialysate in order to obtain the ultrafiltrate. AN69 suplasma concentration at the end of hemodialysis
(μg/mL).To consider redistribution from tissues into the blood
after hemodialysis, Cend was calculated using the follow-
ing equation.
Cend ¼ C’peak– Cpeak
Cpeak is the peak plasma concentration at the first dose
calculated from C1 and C2 and C’peak is the peak plasma
concentration at the second or third dose calculated using
the elimination rate constant calculated from C1 and C2.
However, as patient 2 was on dialysis for 5 h, the con-
centration calculated at 4 h after the start of hemodialysis
was used as Cend in this patient. Clearance of arbekacin by
the dialyzer and the sieving coefficient (SC) at 10 min after
the start of hemodialysis were calculated using the follow-
ing equations.
Arbekacin clearance by the dialyzer
¼ Cint– Coutð Þ = Cint  QB
SC ¼ Cf= C int
Cint is the plasma concentration at the dialyzer inlet (C3
or C7), Cout is the plasma concentration at the dialyzer
outlet (C4 or C8), QB is the blood flow rate, and Cf is
the concentration in the ultrafiltrate (F1 or F2).fusion over 30 min. At 10 min after the start of hemodialysis,
lfonated polyacrylonitrile
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Arbekacin concentration was measured by fluorescence
polarization immunoassay using TDX (Abbott Japan Co.,
Ltd., Chiba, Japan) [13].Statistical analysis
Numbers shown are mean ± standard deviation. Microsoft
Excel 2013 was used for statistical analysis. The unpaired
Student’s t test was used for the adsorption experiment
using cut hemodialysis membranes, and the paired t test
was used for the in vitro adsorption experiment using a
mini-module. A result of p < 0.05 was considered statisti-
cally significant.Results
Qualitative assessment of adsorption using cut
hemodialysis membranes
The rates of arbekacin adsorption onto polysulfone and
AN69 were 6.2 ± 2.9 and 49.8 ± 1.8 %, respectively, with
the rate of arbekacin adsorption onto AN69 being signifi-
cantly higher (Fig. 1b).Quantitative assessment of in vitro adsorption using a
mini-module
When polysulfone was used, there was almost no change
in the circulating arbekacin concentration or the arbeka-
cin concentration in the ultrafiltrate, and the adsorption
rate after 240 min was approximately 0.2 %. When AN69
was used, the circulating arbekacin concentration signifi-
cantly decreased from 30 min after the start of the experi-
ment and the adsorption rate after 240 min was
approximately 68 %. The concentration of arbekacin in
the ultrafiltrate gradually increased and was nearly the
same as the circulating arbekacin concentration after




HD duration (month) 48
DW (kg) 36.0
Dose of arbekacin (mg) 200
Diagnosis VAI
Dialyzer Material Polysulfone AN69
Area (m2) 1.8 1.53
Blood flow rate (mL/min) 200
Dialysate flow rate (mL/min) 500
Dialysis time (min) 240
F female, M male, HD hemodialysis, DW dry weight, VAI vascular access infection, ANClinical study
Characteristics and hemodialysis parameters of the three
patients included in the study (two men and one woman)
are shown in Table 1. Changes in plasma arbekacin con-
centration during hemodialysis when AN69 was used are
shown in Fig. 4, and pharmacokinetic parameters for each
patient are shown in Table 2. For every patient, clearance
was higher and t1/2 was shorter on hemodialysis com-
pared with off hemodialysis. Although clearance markedly
increased and t1/2 markedly decreased for up to 2 h from
the start of dialysis when AN69 was used, clearance was
lower and t1/2 was higher from 2 h onward compared
with values when patients were on hemodialysis with
polysulfone. Ultimately, the rates of arbekacin removal by
hemodialysis for polysulfone and AN69 were 66.7 ± 27.3
and 66.4 ± 21.6 %, respectively, with no significant differ-
ence between them. Arbekacin concentrations in the
inlet, the outlet, and the ultrafiltrate at 10 min after the
start of dialysis when no dialysate was circulated are
shown in Fig. 5. There was little difference between the
arbekacin concentrations in the inlet, the outlet, and the
ultrafiltrate when polysulfone was used. In contrast, the
arbekacin concentrations in the outlet and the ultrafiltrate
were markedly lower than that in the inlet for all patients
when AN69 was used. SC for polysulfone and AN69 were
0.86 ± 0.09 and 0.14 ± 0.07, respectively.
Discussion
Arbekacin is removed by hemodialysis because it has a
low molecular weight of 553 kDa, shows only 3–12 %
protein binding, and has a small volume of distribution
ranging from 0.2 to 0.3 L/kg. Therefore, it is believed
that removal of arbekacin by hemodialysis must be taken
into account when determining dosages for patients on
hemodialysis [5, 6]. Although adsorption onto hemodialysis
membranes has been reported as a mechanism of drug
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Fig. 4 Changes in plasma arbekacin concentration during hemodialysis. a Polysulfone. b AN69. AN69 sulfonated polyacrylonitrile
Table 2 Pharmacokinetic parameters of arbekacin in study
patients
Case 1 2 3
t1/2 (h) Off HD 38 48 62
Polysulfone 1.8 7.9 0.9
On HD 0–1 h 0.7 1.6 .15
AN69 1–2 h 1.0 5.7 3.1
2–4 h 2.8 n.d. 2.2
Off HD 5.2 3.7 2.5
Polysulfone 90 22 170
0–1 h 235 105 101
On HD AN69 1–2 h 172 30 50
2–4 h 59 n.d. 73
CL of arbekacin by daialyzer (mL/min) Polysulfone 3.1 2.4 4.9
AN69 186 195 156
Sieving cofficient Polysulfone 0.99 0.81 .78
AN69 0.05 0.13 0.23
HD hemodialysis, AN69 sulfonated polyacrylonitrile, t1/2 half-life, CL clearance,
n.d. no data
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properties would likely lead to more appropriate dosage
determination. In our adsorption experiment using cut
hemodialysis membranes, we found that arbekacin was
only minimally adsorbed onto polysulfone but was
strongly adsorbed onto AN69. AN69 membranes have a
strong negative charge because their chemical structure
contains sulfonyl groups, whereas polysulfone membranes
have almost no electrical charge. Arbekacin is a basic drug
with amino groups in its chemical structure and an acid
dissociation constant of 8.1, so it is positively charged in
phosphoric acid buffer solution with a pH of 7.4. The
reason why the adsorption rate of arbekacin onto AN69
was high is likely to be the formation of ionic bonds
between the positively charged arbekacin with the nega-
tively charged AN69 membrane. This result is consistent
with findings from a previous study on the influence of
charge of low molecular weight proteins on adsorption
onto hemodialysis membranes [14] and a study showing
that positively charged nafamostat mesilate adsorbed
onto AN69 membrane [9], which indicates that ad-
sorption onto hemodialysis membranes depends on
the charge of adsorbed substances.
In our in vitro adsorption experiment using a mini-
module, we found that when polysulfone was used, the
circulating arbekacin concentration (i.e., the concentration
Fig. 5 Arbekacin concentrations in the dialyzer inlet, outlet, and ultrafiltrate at 10 min after start of hemodialysis. AN69 sulfonated polyacrylonitrile
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and the arbekacin concentration in the ultrafiltrate was the
same as the circulating arbekacin concentration, which
indicates that arbekacin mostly permeated through polysul-
fone without being adsorbed. When AN69 was used, the
circulating arbekacin concentration significantly decreased
from 30 min after the start of the experiment and had
decreased by approximately 68 % after 240 min. Further-
more, the arbekacin concentration in the ultrafiltrate
remained low and barely changed at all over the 90 min
after the start of the experiment, which confirmed that
arbekacin is adsorbed onto AN69. However, the concentra-
tion of arbekacin in the ultrafiltrate gradually increased and
began to closely approach the circulating arbekacin concen-
tration from 180 min after the start of the experiment,
which indicates that adsorption reached saturation.
In our clinical study, we found that clearance was higher
and t1/2 was shorter on hemodialysis compared with off
hemodialysis. Similarly to previous studies [6], this sug-
gests that arbekacin is efficiently removed through
hemodialysis. Furthermore, clearance of arbekacin when
dialysate was not circulated was clearly greater when
AN69 was used compared with when polysulfone was
used (Table 2), which suggests that each membrane has a
different ability to remove arbekacin or a different mech-
anism of removal. SC was close to 1 when polysulfone was
used, which indicates that arbekacin is removed by
ultrafiltration through polysulfone. This means that arbe-
kacin easily passed through polysulfone, indicating that
arbekacin is mainly removed through diffusion when
dialysate is circulated. In contrast, SC was close to 0 when
AN69 was used (Table 2), indicating that there is almostno ultrafiltration of arbekacin through AN69. This is
probably due to increased clearance resulting from the
adsorption of arbekacin onto AN69. This finding strongly
suggests that the adsorption of arbekacin onto AN69 that
we observed in our in vitro experiment (Fig. 2b) also
occurs in clinical practice. Clearance of arbekacin de-
creases, starting from 2 h after the start of hemodialysis
when AN69 is used. We also observed adsorption satur-
ation from the 2-h mark onward in our in vitro adsorption
experiment (Fig. 2b), which indicates that adsorption
saturation also occurs in clinical practice. The results of
our clinical study suggest that arbekacin is adsorbed onto
AN69 in clinical practice as well as in vitro.
However, the clinical trial had some limitations. The
sample size was small, and blood samples were collected
at different time points with polysulfone than with AN69
to minimize patient discomfort. Therefore, additional re-
search regarding the clinical impact of the adsorption of
arbekacin onto AN69 will be necessary.
Many studies in which in vitro drug adsorption experi-
ments were conducted have been published [8, 10], but
a mini-module using dialyzers used in clinical practice
has not previously been used to evaluate the adsorption
properties of drugs. In a previous in vitro adsorption
experiment that we conducted, we similarly found that
the rate of arbekacin adsorption onto AN69 was ap-
proximately 70 % [11]. However, the experimental sys-
tem used dialyzers used in clinical practice along with
arbekacin solution dissolved in bovine serum (3 L) and
was at 1/3 scale, so it required a large volume of bovine
serum and drug. In the present study, we found adsorp-
tion rates similar to rates from previous studies and
Urata et al. Renal Replacement Therapy  (2016) 2:35 Page 8 of 8removal rates similar to rates from clinical studies. This
suggests that our quantitative assessment system using
the “mini-module” that we created for this study is suit-
able. In addition, the mini-module uses low volumes of
solvent and drug, making it an easy-to-use and low-cost
method of assessment.
Conclusions
We confirmed that arbekacin interacts with the AN69
membrane through adsorption. In addition, we found that
our in vitro experimental system using a “mini-module”
that we created for this study is an easier method for asses-
sing the adsorption of drugs onto hemodialysis membranes.
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